Work Here?
About PostEra
Industries
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$24.2M
Headquarters
Santa Clara, California
Founded
2019
Overview
PostEra.ai focuses on improving the drug discovery process in the biopharmaceutical industry by using machine learning to speed up the Design-Make-Test cycle of medicinal chemistry. Their technology helps pharmaceutical companies, like Amgen and Pfizer, to develop more effective treatments more quickly than traditional methods. PostEra.ai collaborates with major industry players, securing over $1 billion in partnerships, including a $260 million AI Lab partnership with Pfizer and a $68 million project funded by the NIH to develop antivirals. Unlike many competitors, PostEra.ai's business model relies heavily on strategic collaborations, allowing them to provide tailored AI solutions that reduce the time and costs associated with drug development. The company's goal is to enhance the efficiency of drug discovery, ultimately bringing better cures to patients faster.
Simplify's Take
What believers are saying
- PostEra's AI partnerships with Amgen and Pfizer enhance its market credibility.
- The $68M NIH-funded antiviral collaboration boosts PostEra's research capabilities.
- AI-driven personalized medicine trends align with PostEra's technology focus.
What critics are saying
- Increased competition from companies like Insilico Medicine and Exscientia.
- Over-reliance on major partnerships with Pfizer and Amgen poses financial risks.
- Regulatory challenges could delay AI-driven drug approval processes.
What makes PostEra unique
- PostEra integrates AI and machine learning to expedite medicinal chemistry processes.
- The company has secured over $1 billion in AI drug discovery collaborations.
- PostEra leads the COVID Moonshot, the largest open-science drug discovery effort.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$24.1M
Above
Industry Average
Funded Over
2 Rounds
Y CombinatorIndustry standards
Benefits
Performance Bonus
Stock Options
Professional Development Budget
Conference Attendance Budget
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -2%2 year growth
↑ 2%PostEra is building a modern biopharma, using machine learning to accelerate medicinal chemistry, to develop cures for diseases, faster.
Optibrium, a leading developer of software and AI for small molecule discovery, and PostEra, an AI-first biotechnology company with advanced machine learning (ML) technology for preclinical discovery, today announced a collaboration to integrate Optibrium’s StarDrop platform with PostEra’s Manifold software.
BOSTON, May 19, 2022 /PRNewswire/ -- PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding
What You Should Know: PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients. PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and ... Read More
PostEra, a biotechnology company specialising in machine learning for drug discovery, today announced that it has received a grant of £100,000 from the independent medical charity LifeArc to support an international effort to rapidly develop a potential antiviral candidate for COVID-19.
There are no jobs for PostEra right now.
Find jobs on Simplify and start your career today
About PostEra
Industries
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$24.2M
Headquarters
Santa Clara, California
Founded
2019
There are no jobs for PostEra right now.
Find jobs on Simplify and start your career today